transmedics inc. is the world’s leader in portable ex-vivo perfusion and assessment of donor organs for transplantation. the company was founded to address the need for more and better organs for transplantation, and is focused on transforming the standard of care – increasing organ utilization, improving patient outcomes, and reducing transplant costs throughout the heath care system. the ocs™ lung and ocs™ heart systems are ce-marked and in commercial use outside the us, and are currently being reviewed by the fda for u.s. market access. the ocs™ liver is in an fda pivotal trial (the ocs™ liver protect trial) in the united states and a ce-mark trial in (the revive trial) in europe.
Company profile
Ticker
TMDX
Exchange
Website
CEO
Waleed H. Hassanein
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
SEC CIK
Corporate docs
Subsidiaries
TransMedics, Inc. • TransMedics, B.V. • TransMedics Pty Ltd. • TransMedics GmbH • Summit Aviation, Inc. • Northside Property Group, LLC ...
TMDX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
10 Apr 24
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
8-K
Completion of Acquisition or Disposition of Assets
12 Mar 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
TransMedics Reports Fourth Quarter and Full Year 2023 Financial Results
26 Feb 24
8-K
Completion of Acquisition or Disposition of Assets
6 Feb 24
8-K
Completion of Acquisition or Disposition of Assets
29 Jan 24
8-K
Completion of Acquisition or Disposition of Assets
2 Jan 24
8-K
Completion of Acquisition or Disposition of Assets
19 Dec 23
Transcripts
TMDX
Earnings call transcript
2023 Q4
26 Feb 24
TMDX
Earnings call transcript
2023 Q3
6 Nov 23
TMDX
Earnings call transcript
2023 Q2
3 Aug 23
TMDX
Earnings call transcript
2023 Q1
1 May 23
TMDX
Earnings call transcript
2022 Q4
22 Feb 23
TMDX
Earnings call transcript
2022 Q3
3 Nov 22
TMDX
Earnings call transcript
2022 Q2
2 Aug 22
TMDX
Earnings call transcript
2022 Q1
4 May 22
TMDX
Earnings call transcript
2021 Q4
24 Feb 22
TMDX
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
4
Waleed H Hassanein
18 Apr 24
4
Waleed H Hassanein
12 Apr 24
4
Tamer I Khayal
10 Apr 24
144
Notice of proposed sale of securities
10 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
4
Tamer I Khayal
5 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
4
Stephen Gordon
2 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
144
Notice of proposed sale of securities
18 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 427.61 mm | 427.61 mm | 427.61 mm | 427.61 mm | 427.61 mm | 427.61 mm |
Cash burn (monthly) | 51.78 mm | (no burn) | 9.45 mm | 3.23 mm | 2.29 mm | 2.11 mm |
Cash used (since last report) | 352.05 mm | n/a | 64.21 mm | 21.94 mm | 15.56 mm | 14.37 mm |
Cash remaining | 75.56 mm | n/a | 363.40 mm | 405.67 mm | 412.05 mm | 413.24 mm |
Runway (months of cash) | 1.5 | n/a | 38.5 | 125.7 | 180.0 | 195.5 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 218 |
Opened positions | 31 |
Closed positions | 52 |
Increased positions | 93 |
Reduced positions | 66 |
13F shares | Current |
---|---|
Total value | 1.90 tn |
Total shares | 34.89 mm |
Total puts | 167.40 k |
Total calls | 498.00 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
FMR | 4.71 mm | $258.14 bn |
BLK Blackrock | 2.45 mm | $134.10 bn |
Vanguard | 1.81 mm | $99.34 bn |
MCQEF Macquarie | 1.71 mm | $93.67 bn |
Fred Alger Management | 1.57 mm | $86.21 bn |
Allspring Global Investments | 1.27 mm | $69.62 bn |
IVZ Invesco | 1.25 mm | $68.62 bn |
Credit Suisse | 1.13 mm | $61.97 bn |
Driehaus Capital Management | 1.00 mm | $54.80 bn |
Eventide Asset Managment | 925.36 k | $50.66 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Apr 24 | Waleed H Hassanein | Common Stock | Sell | Dispose S | No | Yes | 95.12 | 4,000 | 380.48 k | 74,087 |
17 Apr 24 | Waleed H Hassanein | Common Stock | Option exercise | Acquire M | No | Yes | 13.28 | 4,000 | 53.12 k | 78,087 |
17 Apr 24 | Waleed H Hassanein | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 13.28 | 4,000 | 53.12 k | 234,000 |
10 Apr 24 | Waleed H Hassanein | Common Stock | Sell | Dispose S | No | Yes | 95.09 | 12,000 | 1.14 mm | 74,087 |
10 Apr 24 | Waleed H Hassanein | Common Stock | Option exercise | Acquire M | No | Yes | 13.28 | 12,000 | 159.36 k | 86,087 |
10 Apr 24 | Waleed H Hassanein | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 13.28 | 12,000 | 159.36 k | 238,000 |
9 Apr 24 | Tamer I Khayal | Common Stock | Sell | Dispose S | No | Yes | 91.11 | 4,980 | 453.73 k | 25,185 |
9 Apr 24 | Tamer I Khayal | Common Stock | Sell | Dispose S | No | Yes | 90.14 | 10,532 | 949.35 k | 30,165 |
9 Apr 24 | Tamer I Khayal | Common Stock | Option exercise | Acquire M | No | Yes | 38.46 | 7,171 | 275.80 k | 40,697 |
9 Apr 24 | Tamer I Khayal | Common Stock | Option exercise | Acquire M | No | Yes | 16.14 | 8,341 | 134.62 k | 33,526 |
News
10 Health Care Stocks Whale Activity In Today's Session
3 Apr 24
Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
3 Apr 24
(TMDX) - Analyzing TransMedics Gr's Short Interest
29 Mar 24
Cracking The Code: Understanding Analyst Reviews For TransMedics Gr
28 Mar 24
Piper Sandler Initiates Coverage On TransMedics Gr with Overweight Rating, Announces Price Target of $95
28 Mar 24
Press releases
TransMedics to Report First Quarter 2024 Financial Results on April 30, 2024
16 Apr 24
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
8 Apr 24
TMDX INVESTOR NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation - TMDX
2 Mar 24
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation – TMDX
1 Mar 24
TransMedics Group Investors: Company Investigated by the Portnoy Law Firm
27 Feb 24